RxDoctor Payments Data

Michael Kreager, MD

Cardiovascular Disease · Kenosha, WINPI 1609850791

Payments from drug & device makers

$3,564in general payments, 2019–2025

Across 213 payments — averaging $16.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$620
  • AstraZeneca$409
  • Novo Nordisk$364
  • Pfizer$320
  • Johnson & Johnson$285
  • Boehringer Ingelheim$248
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$3,46497%
  • Education$1003%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,564 in reported general payments places this provider in the 65th percentile of 322 cardiovascular disease providers in Wisconsin.

See all cardiovascular disease providers in Wisconsin

Medicare billing

Part B allowed, 2024
$177,360
Medicare patients
760
Services billed
1,959

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban424$495,938
XareltoRivaroxaban64$83,506
EntrestoSacubitril/Valsartan23$30,567
Repatha SureclickEvolocumab34$25,505
BrilintaTicagrelor23$23,184
Repatha SyringeEvolocumab24$15,239
JardianceEmpagliflozin11$12,903
Praluent PenAlirocumab15$12,462
Propafenone Hcl65$7,729
Metoprolol Succinate325$5,862
Losartan Potassium339$3,514
Atorvastatin Calcium306$2,843
ClopidogrelClopidogrel Bisulfate211$2,715
Ezetimibe125$2,459
Enalapril Maleate71$2,260

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$320$495,938424 claims
Johnson & JohnsonXarelto$285$83,50664 claims
NovartisEntresto$198$30,56723 claims
AstraZenecaBrilinta$409$23,18423 claims
Boehringer IngelheimJardiance$248$12,90311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 322 cardiovascular disease providers in Wisconsin.

Other cardiovascular disease in Kenosha

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →